Drug Trial Radar · NCT06411860
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 12, 2024
Primary completion
Nov 29, 2024
Study completion Dec 11, 2024
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is: • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.
Conditions
- Basic Science
Interventions
PlaceboOther
Participants will receive a subcutaneous (SC) injection of placebo.
OlpasiranDrug
Participants will receive a SC injection of olpasiran at dose level 1 or 2.
MoxifloxacinDrug
Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Placebo-corrected Change From Baseline in QT Corrected for Heart Rate (HR) Interval Based on the Fridericia Correction (QTcF) (ΔΔQTcF) After Olpasiran DosingTime frame: Day 3 of Treatment Period 4 (up to approximately 9.5 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit Limited - Leeds
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.